Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
JSPR Jasper Therapeutics	$2.86 -1.6%	$3.73	$2.27 ▼ $26.05	$46.39M	2.7	494,184 shs	85,586 shs
KLRS Kalaris Therapeutics	$3.60 +16.9%	$2.57	$2.14 ▼ $24.15	$67.32M	0.49	45,576 shs	319,513 shs
MBIO Mustang Bio	$1.55 +1.0%	$1.75	$0.89 ▼ $21.95	$11.19M	2.22	2.48 million shs	51,914 shs
TELO Telomir Pharmaceuticals	$1.48 -0.3%	$1.59	$1.12 ▼ $8.40	$47.65M	-0.67	1.76 million shs	63.19 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
JSPR Jasper Therapeutics	-0.68%	+1.75%	-6.45%	-48.94%	-85.68%
KLRS Kalaris Therapeutics	+20.31%	+19.84%	+5.48%	+4.05%	+307,999,900.00%
MBIO Mustang Bio	+1.32%	-7.27%	-19.47%	+14.18%	-89.92%
TELO Telomir Pharmaceuticals	-0.67%	+2.07%	-29.52%	-29.52%	-71.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
JSPR Jasper Therapeutics	2.9523 of 5 stars	4.3	4.0	1.1	1.7	0.0
KLRS Kalaris Therapeutics	0.5147 of 5 stars	1.0	0.0	2.6	3.3	0.0
MBIO Mustang Bio	1.0634 of 5 stars	0.0	5.0	2.7	0.0	0.6
TELO Telomir Pharmaceuticals	2.7993 of 5 stars	3.8	2.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	907.01% Upside
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	-16.67% Downside
MBIO Mustang Bio	0.00	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	3.50	Strong Buy	$15.00	916.26% Upside

Current Analyst Ratings Breakdown

Latest MBIO, JSPR, KLRS, and TELO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	$0.40 per share	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
JSPR Jasper Therapeutics	-$71.27M	-$6.01	N/A	N/A	N/A	N/A	-172.28%	-128.34%	11/6/2025 (Estimated)
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A
MBIO Mustang Bio	-$15.75M	-$78.00	N/A	N/A	N/A	N/A	N/A	-29.49%	11/6/2025 (Estimated)
TELO Telomir Pharmaceuticals	-$16.53M	-$0.54	N/A	N/A	N/A	N/A	-4,595.08%	-1,750.91%	11/11/2025 (Estimated)

Latest MBIO, JSPR, KLRS, and TELO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	TELO Telomir Pharmaceuticals	-$0.08	-$0.17	-$0.09	-$0.17	N/A	N/A
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A
8/8/2025	Q2 2025	MBIO Mustang Bio	N/A	-$0.19	N/A	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
MBIO Mustang Bio	N/A	N/A	N/A	N/A	N/A
TELO Telomir Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
JSPR Jasper Therapeutics	N/A	2.10	2.10
KLRS Kalaris Therapeutics	N/A	11.98	11.98
MBIO Mustang Bio	N/A	1.30	1.30
TELO Telomir Pharmaceuticals	N/A	2.39	2.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
JSPR Jasper Therapeutics	79.85%
KLRS Kalaris Therapeutics	66.05%
MBIO Mustang Bio	9.95%
TELO Telomir Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
JSPR Jasper Therapeutics	4.60%
KLRS Kalaris Therapeutics	74.99%
MBIO Mustang Bio	0.21%
TELO Telomir Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
JSPR Jasper Therapeutics	20	16.25 million	15.51 million	Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
MBIO Mustang Bio	100	7.24 million	7.23 million	Not Optionable
TELO Telomir Pharmaceuticals	1	32.28 million	N/A	N/A

MBIO, JSPR, KLRS, and TELO Headlines

Recent News About These Companies

Telomir stock soars after drug candidate shows promising epigenetic effects

3 hours ago | za.investing.com

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging ...

3 hours ago | kansascity.comK

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

August 28 at 8:00 AM | accessnewswire.comA

TELO Makes Progress Toward Human Trials

August 15, 2025 | msn.com

Telomir-1 inhibits key histone demethylase enzymes in vitro

August 12, 2025 | bioworld.comB

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic ...

August 8, 2025 | kansascity.comK

Telomir Flat on Trial Data Release

August 7, 2025 | baystreet.ca

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

August 7, 2025 | accessnewswire.comA

Telomir Pharmaceuticals (TELO) Expected to Announce Earnings on Tuesday

August 6, 2025 | marketbeat.com

Telomir Pharmaceuticals Announces Promising Preclinical Results

July 26, 2025 | theglobeandmail.com

Telomir Pharmaceuticals stock surges on promising Progeria treatment results

July 25, 2025 | investing.com

TELO Announces Another Important Breakthrough

July 25, 2025 | finance.yahoo.com

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

July 24, 2025 | accessnewswire.comA

Telomir Pharmaceuticals Skyrockets 150% on Breakthrough Preclinical Cancer Results

July 18, 2025 | msn.com

Telomir Pharmaceuticals stock soars after promising cancer treatment data

July 18, 2025 | investing.com

Telomir Pharma Jumps In After-Hours Trading After Drug Reverses Damage In Progeria Cells; Retail Eyes Bigger Gains

July 18, 2025 | msn.com

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

July 18, 2025 | accessnewswire.comA

Telomir says data show Telomir-1 reversed epigenetic silencing

July 17, 2025 | msn.com

Telomir Pharmaceuticals Reveals Promising Preclinical Cancer Results

July 17, 2025 | tipranks.com

Telomir Pharmaceuticals Inc News (TELO) - Investing.com

July 1, 2025 | investing.com

Telomir Pharmaceuticals Reports Positive Preclinical Data

June 18, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBIO, JSPR, KLRS, and TELO Company Descriptions

Jasper Therapeutics NASDAQ:JSPR

$2.86 -0.05 (-1.55%)

Closing price 03:58 PM Eastern

Extended Trading

$2.85 0.00 (-0.18%)

As of 04:04 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Kalaris Therapeutics NASDAQ:KLRS

$3.60 +0.52 (+16.88%)

As of 03:45 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Mustang Bio NASDAQ:MBIO

$1.54 +0.02 (+0.98%)

Closing price 03:56 PM Eastern

Extended Trading

$1.54 0.00 (0.00%)

As of 04:04 PM Eastern

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.

Telomir Pharmaceuticals NASDAQ:TELO

$1.48 0.00 (-0.27%)

Closing price 03:59 PM Eastern

Extended Trading

$1.44 -0.03 (-2.30%)

As of 04:05 PM Eastern

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time